Literature DB >> 17151816

The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol.

Mehmet Kanadaşi1, Murat Cayli, Mustafa Demirtaş, Tamer Inal, Mesut Demir, Mevlut Koç, Mahir Avkaroğullari, Yurdaer Dönmez, Ayhan Usal, Cumhur C Alhan, Mustafa San.   

Abstract

We investigated the effects of atorvastatin on inflammation and cardiac events during the inpatient period and initial 6-month follow-up in acute coronary syndrome (ACS) patients with low low-density lipoprotein (LDL) cholesterol level. One hundred and twelve consecutive ACS patients with LDL cholesterol less than 100 mg/dl were included in the study (mean 78.2+/-12.3 mg/dl). While 70 randomly selected patients received a dose of 40 mg atorvastatin within the first 24 h on top of their standard treatment as the atorvastatin group, the remaining 42 patients considered as the control group were given the standard treatment only, i.e., without any lipid-lowering drug therapy. Lipid profile, high-sensitivity C-reactive protein (hsCRP), and plasma amyloid A (SAA) levels were measured in all patients within the first 24 h of chest pain, on the 5th day, and in the 6th month. During the inpatient period and subsequent 6-month follow-up, all episodes of angina, reinfarction, revascularization, heart failure, rehospitalization, cardiac mortality, and total number of cardiac events were recorded. In the atorvastatin group, hsCRP and SAA values on the 5th day and in the 6th month compared to the first 24 h were significantly lower than those of the control group (P<0.0001). Mean LDL cholesterol level was significantly decreased in the atorvastatin group (55.7+/-17.7 mg/dl), but there was no significant change in the control group at the 6th month. The frequency of heart failure during the inpatient period and angina, unstable angina pectoris, heart failure, and revascularization in the first 6 months were also significantly reduced in the atorvastatin group. Atorvastatin started in the first 24 h reduces inflammation and improves the prognosis during both the inpatient period and the first 6 months of clinical follow-up in ACS patients with low LDL cholesterol levels.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17151816     DOI: 10.1007/s00380-005-0901-1

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  23 in total

1.  Improvement of arterial stiffness by the antioxidant and anti-inflammatory effects of short-term statin therapy in patients with hypercholesterolemia.

Authors:  Takashi Matsuo; Kazunori Iwade; Naomi Hirata; Michio Yamashita; Haruhiko Ikegami; Naohide Tanaka; Masahiko Aosaki; Hiroshi Kasanuki
Journal:  Heart Vessels       Date:  2005-02       Impact factor: 2.037

2.  Risks and benefits of early treatment of acute myocardial infarction with an angiotensin-converting enzyme inhibitor in patients with a history of arterial hypertension: analysis of the GISSI-3 database.

Authors:  Fausto Avanzini; Gabriele Ferrario; Luigi Santoro; Paolo Peci; Paolo Giani; Eugenio Santoro; Maria Grazia Franzosi; Gianni Tognoni
Journal:  Am Heart J       Date:  2002-12       Impact factor: 4.749

3.  C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis.

Authors:  T P Zwaka; V Hombach; J Torzewski
Journal:  Circulation       Date:  2001-03-06       Impact factor: 29.690

4.  Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients.

Authors:  T Killip; J T Kimball
Journal:  Am J Cardiol       Date:  1967-10       Impact factor: 2.778

5.  Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications.

Authors:  E M Macy; T E Hayes; R P Tracy
Journal:  Clin Chem       Date:  1997-01       Impact factor: 8.327

Review 6.  Novel clinical markers of vascular wall inflammation.

Authors:  G J Blake; P M Ridker
Journal:  Circ Res       Date:  2001-10-26       Impact factor: 17.367

7.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

8.  Early use of pravastatin in patients with acute myocardial infarction undergoing coronary angioplasty.

Authors:  Meral Kayikçioğlu; Levent Can; Hakan Kültürsay; Serdar Payzin; Cüneyt Turkoğlu
Journal:  Acta Cardiol       Date:  2002-08       Impact factor: 1.718

9.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

10.  Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction.

Authors:  L Lacoste; J Y Lam; J Hung; G Letchacovski; C B Solymoss; D Waters
Journal:  Circulation       Date:  1995-12-01       Impact factor: 29.690

View more
  10 in total

1.  Circulating platelet and neutrophil activation correlates with the clinical course of unstable angina.

Authors:  Satoshi Murasaki; Kagari Murasaki; Kenjiro Tanoue; Masatoshi Kawana; Nobuhisa Hagiwara; Hiroshi Kasanuki
Journal:  Heart Vessels       Date:  2007-11-26       Impact factor: 2.037

2.  Accelerated decline in renal function after acute myocardial infarction in patients with high low-density lipoprotein-cholesterol to high-density lipoprotein-cholesterol ratio.

Authors:  Satoshi Okumura; Masaki Sakakibara; Ryo Hayashida; Yasushi Jinno; Akihito Tanaka; Koji Okada; Mutsuharu Hayashi; Hideki Ishii; Toyoaki Murohara
Journal:  Heart Vessels       Date:  2013-01-29       Impact factor: 2.037

3.  Paradoxical impact of decreased low-density lipoprotein cholesterol level at baseline on the long-term prognosis in patients with acute coronary syndrome.

Authors:  Takuya Nakahashi; Hayato Tada; Kenji Sakata; Yohei Yakuta; Yoshihiro Tanaka; Akihiro Nomura; Tadatsugu Gamou; Hidenobu Terai; Yuki Horita; Masatoshi Ikeda; Masanobu Namura; Masayuki Takamura; Kenshi Hayashi; Masakazu Yamagishi; Masa-Aki Kawashiri
Journal:  Heart Vessels       Date:  2017-12-29       Impact factor: 2.037

4.  Effects of drug-eluting stents on systemic inflammatory response in patients with unstable angina pectoris undergoing percutaneous coronary intervention.

Authors:  Nihat Ozer; Burak Tangurek; Fatih Firat; Songul Ozer; Zeynep Tartan; Recep Ozturk; Batuhan Ozay; Figen Ciloglu; Hale Yilmaz; Nese Cam
Journal:  Heart Vessels       Date:  2008-04-04       Impact factor: 2.037

5.  Immediate effect of fluvastatin on lipid levels in acute coronary syndrome.

Authors:  Petr Ostadal; David Alan; Jiri Vejvoda; Jana Cepova; Jiri Kukacka; Peter Blasko; Lucia Martinkovicova; Jan Vojacek
Journal:  Mol Cell Biochem       Date:  2007-07-25       Impact factor: 3.396

6.  Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases.

Authors:  Hiroyuki Oka; Satoshi Ikeda; Seiji Koga; Yoshiyuki Miyahara; Shigeru Kohno
Journal:  Heart Vessels       Date:  2008-07-23       Impact factor: 2.037

7.  Circulating levels of autoantibodies to oxidized low-density lipoprotein and C-reactive protein levels correlate with endothelial function in resistance arteries in men with coronary heart disease.

Authors:  Milita Crisby; Karolina Kublickiene; Loghman Henareh; Stefan Agewall
Journal:  Heart Vessels       Date:  2009-04-01       Impact factor: 2.037

8.  Effect of atorvastatin on testosterone levels.

Authors:  Muhammad Ismail Shawish; Bahador Bagheri; Vijaya M Musini; Stephen P Adams; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2021-01-22

9.  The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis.

Authors:  Jie Zhang; Xinyi Wang; Wende Tian; Tongxin Wang; Jundi Jia; Runmin Lai; Tong Wang; Zihao Zhang; Luxia Song; Jianqing Ju; Hao Xu
Journal:  Front Cardiovasc Med       Date:  2022-07-27

10.  Impact of Previous Stroke on Short-Term Myocardial Reinfarction in Patients With Acute ST Segment Elevation Myocardial Infarction: An Observational Multicenter Study.

Authors:  Li Tian; Yanmin Yang; Jun Zhu; Lisheng Liu; Yan Liang; Jiandong Li; Bo Yu
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.